DE3405663A1 - Process for the preparation of scyllo-inositol - Google Patents
Process for the preparation of scyllo-inositolInfo
- Publication number
- DE3405663A1 DE3405663A1 DE19843405663 DE3405663A DE3405663A1 DE 3405663 A1 DE3405663 A1 DE 3405663A1 DE 19843405663 DE19843405663 DE 19843405663 DE 3405663 A DE3405663 A DE 3405663A DE 3405663 A1 DE3405663 A1 DE 3405663A1
- Authority
- DE
- Germany
- Prior art keywords
- myo
- inositol
- scyllo
- inosose
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims abstract description 32
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 13
- 229960000367 inositol Drugs 0.000 claims abstract description 13
- VYEGBDHSGHXOGT-ZLIBEWLCSA-N (2r,3s,5r,6s)-2,3,4,5,6-pentahydroxycyclohexan-1-one Chemical compound OC1[C@H](O)[C@@H](O)C(=O)[C@@H](O)[C@@H]1O VYEGBDHSGHXOGT-ZLIBEWLCSA-N 0.000 claims abstract description 12
- 230000003647 oxidation Effects 0.000 claims abstract description 12
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 12
- 238000005886 esterification reaction Methods 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 230000032050 esterification Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 abstract description 4
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- -1 alkali metal acetates Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- ZAVYLQGLQYIKKF-OTWZMJIISA-N (2r,3r,4s)-2,3,4,6-tetrahydroxy-5-oxohexanal Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C=O ZAVYLQGLQYIKKF-OTWZMJIISA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VWPUAXALDFFXJW-UHFFFAOYSA-N benzenehexol Chemical compound OC1=C(O)C(O)=C(O)C(O)=C1O VWPUAXALDFFXJW-UHFFFAOYSA-N 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
- C07C35/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with more than one hydroxy group bound to the ring
- C07C35/16—Inositols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Verfahren zur Herstellung von scyllo-InositProcess for the production of scyllo-inositol
Verfahren zur Herstellung von scyllo-Inosit Die Erfindung betrifft ein Verfahren zur Herstellung von scyllo-Inosit aus myo-Inosit. Process for the preparation of scyllo-inositol The invention relates to a process for the production of scyllo-inositol from myo-inositol.
Es sind bereits eine ganze Reihe von Darstellungsverfahren des in Flora und Fauna weit verbreiteten Naturstoffes scyllo-Inosit bekannt [zum Beispiel durch biologische Oxydation von myo-Inosit zu myo-Insose und Reduktion (Th. Posternak, Helv. Chim. Acta, 24, 1045 (1941); durch Hydrierung von Hexahydroxybenzol (R.C. Anderson und E.S. Wallis, J. Am. Chem. Soc. 70, 293 (1948); durch Reduktion von Pentaacetyl-myo-inosose mit NaBH4 und Verseifung (N.Z. Stanazev und M. Kates, J. Org. Chem. 26, 912 (1961); durch basische Kondensation von "D-xylo-Hexos-5-ulose" zu myo-Inosose und Reduktion (D.F. Kiely und H.G. Fletscher, J. Am. Chem. Soc. 90, 3289 (1968) und durch nucleophile Öffnung von cis-Trioxatris-a-homobenzol (R. Schwesinger, H. Fritz und H. Prinzbach, Angew. Chem. 85, 1110 (1973)1.A whole series of display methods for the in Flora and fauna widely known natural substance scyllo-inositol [for example through biological oxidation of myo-inositol to myo-insosis and reduction (Th. Posternak, Helv. Chim. Acta, 24, 1045 (1941); by hydrogenation of hexahydroxybenzene (R.C. Anderson and E.S. Wallis, J. Am. Chem. Soc. 70: 293 (1948); by reducing Pentaacetyl-myo-inosose with NaBH4 and saponification (N.Z. Stanazev and M. Kates, J. Org. Chem. 26, 912 (1961); by basic condensation of "D-xylo-Hexos-5-ulose" on myo-inososis and reduction (D.F. Kiely and H.G. Fletscher, J. Am. Chem. Soc. 90, 3289 (1968) and by nucleophilic opening of cis-trioxatris-a-homobenzene (R. Schwesinger, H. Fritz and H. Prinzbach, Angew. Chem. 85, 1110 (1973) 1.
Die Methode der selektiven, katalytischen Oxidation der axialen Hydroxylgruppe des myo-Inosits mit Pt/02 [K. Heyns und H. Paulsen, Chem. Ber. 86, 833 (1953) bzw. Angew.The method of selective, catalytic oxidation of the axial hydroxyl group des myo-inositol with Pt / 02 [K. Heyns and H. Paulsen, Chem. Ber. 86, 833 (1953) or Applied
Chem. 69, 600 (1957)] zur myo-Inosose und deren Reduktion [D. Reymond, Helv. Chim. Acta, 59, 492 (1957)3 schien in möglichst wenigen Synthese- und Reinigungsstufen, ausgehend von billigen und leicht zugänglichen Ausgangsmaterialien, zum gewünschten Produkt zu führen.Chem. 69, 600 (1957)] on myo-inososis and its reduction [D. Reymond, Helv. Chim. Acta, 59, 492 (1957) 3 appeared in as few synthetic and purification stages, starting from cheap and easily accessible raw materials, lead to the desired product.
Da bei der Oxidation des myo-Inosits jedoch lediglich Umsätze von 75-80 % erreicht werden, ist eine Abtrennung des nicht umgesetzten Ausgangsmaterials notwendig, um bei der nachfolgenden Reduktion scyllo-Inosit in hoher Reinheit zu erhalten. Die von Heyns und Paulsen vorgeschlagene Methode über das Phenylhydrazon der myo-Inosose ist im halbtechnischen oder technischen Maßstab nicht mit vertretbarem Aufwand durchführbar und würde überdies zu einer unerwünschten Abwasserbelastung führen. Eigene Versuche zeigten weiterhin, daß die Phenylhydrazonmethode außerordentlich schwierig reproduzierbar war.Since, however, only sales of 75-80% are achieved, is a separation of the unreacted starting material necessary to obtain scyllo-inositol in high purity during the subsequent reduction obtain. The method proposed by Heyns and Paulsen via the phenylhydrazone the myo-inososis is not justifiable on a semi-industrial or technical scale Effort can be carried out and, moreover, would result in undesirable wastewater pollution to lead. Our own tests also showed that the phenylhydrazone method is extraordinary was difficult to reproduce.
Aufgabe der vorliegenden Erfindung war es nun, ein verbessertes Verfahren zur Synthese von scyllo-Inosit sowie zur Abtrennung von nicht umgesetztem myo-Inosit aus dessen myo-Inosose enthaltenden Oxidationsprodukten zu finden, die die beschriebenen Nachteile nicht oder nur in geringerem Maße aufweisen.The object of the present invention was now to provide an improved process for the synthesis of scyllo-inositol and for the separation of unreacted myo-inositol from its myo-inosose containing oxidation products that contain the described No disadvantages or only to a lesser extent.
Diese Aufgabe wurde dadurch gelöst, daß man das nach der Oxidation des myo-Inosits erhaltene Gemisch einer Veresterung unterwirft und die myo-Inosose als gut kristallisierenden Ester selektiv auskristallisiert. Diese Ester können anschließend durch Reduktion und Hydrolyse in scyllo-Inosit überführt werden.This problem has been solved by doing that after the oxidation the mixture obtained from the myo-inosite is subjected to esterification and the myo-inososis selectively crystallized out as a well-crystallizing ester. These esters can subsequently converted into scyllo-inositol by reduction and hydrolysis.
Gegenstand der Erfindung ist somit ein Verfahren zur Herstellung von scyllo-Inosit aus myo-Inosit über myo-Inosose, dadurch gekennzeichnet, daß man das nach der Oxidation erhaltene Gemisch einer Veresterung unterwirft, bei der ein gut kristallisierender Ester der myo-Inosose entsteht, der anschließend durch Reduktion und Hydrolyse in scyllo-Inosit überführt wird, sowie ein Verfahren zur Abtrennung von nicht umgesetztem myo-Inosit aus dessen myo-Inosose enthaltenden Oxidationsprodukten, dadurch gekennzeichnet, daß die myo-Inosose als gut kristallisierender Ester selektiv auskristallisiert wird.The invention thus provides a method for producing scyllo-inositol from myo-inositol via myo-inosose, characterized in that the subjecting the mixture obtained after the oxidation to an esterification, at which creates a well-crystallizing ester of myo-inosose, which subsequently is converted into scyllo-inositol by reduction and hydrolysis, and a process for the separation of unreacted myo-inositol from its myo-inosose containing Oxidation products, characterized in that the myo-Inosose as well crystallizing Ester is selectively crystallized out.
Die Oxidation von myo-Inosit kann prinzipiell nach allen bekannten Verfahren durchgeführt werden, beispielsweise durch biologische Oxidation oder durch selektive Oxidationsmittel wie N-Bromsuccinimid, Silbercarbonat/ Celite oder Chlor/Pyridin. Vorzugsweise erfolgt die Oxidation in wässeriger Lösung bei 30-800, insbesondere bei 45-60° als katalytische Dehydrierung mit Edelmetallkatalysatoren, vorzugsweise Platinkatalysatoren, und Sauerstoff.The oxidation of myo-inositol can in principle according to all known Processes are carried out, for example by biological oxidation or by selective oxidizing agents such as N-bromosuccinimide, silver carbonate / Celite or chlorine / pyridine. The oxidation is preferably carried out in aqueous solution at 30-800, in particular at 45-60 ° as catalytic dehydrogenation with noble metal catalysts, preferably Platinum catalysts, and oxygen.
Das Reaktionsgemisch kann ohne weitere Reinigungsoperationen verestert werden. Vorzugsweise wird das Reaktionsgemisch nach Entfernen des Katalysators eingedampft. Der Rückstand wird mit einer Säure oder einem ihrer reaktionsfähigen Derivate verestert. Als reaktionsfähige Derivate eignen sich insbesondere Säurehalogenide, vor allem die Chloride und Bromide, Anhydride (auch gemischte Anhydride), ferner Azide oder Ester, insbesondere Alkylester mit 1-4 C-Atomen in der Alkylgruppe.The reaction mixture can be esterified without further purification operations will. The reaction mixture is preferably evaporated after the catalyst has been removed. The residue is esterified with an acid or one of its reactive derivatives. Acid halides, above all, are particularly suitable as reactive derivatives the chlorides and bromides, anhydrides (also mixed anhydrides), also azides or Esters, especially alkyl esters with 1-4 carbon atoms in the alkyl group.
Die Veresterung kann in Gegenwart eines inerten Lösungsmittels durchgeführt werden. Gut geeignet sind insbesondere Amide wie Dimethylformamid, Dimethylacetamid, 1,3-Dimethyl-2-imidazolidinon oder Phosphorsäurehexamethyltriamid und Sulfoxide wie Dimethylsulfoxid oder Sulfolan. Die Veresterung kann auch vorteilhaft in Abwesenheit eines Lösungsmittels, z. B. durch einfaches Mischen der Komponenten, gegebenenfalls in Gegenwart einer starken Säure, durchgeführt werden. Die Reaktionstemperatur liegt gewöhnlich zwischen -200 und 800, vorzugsweise zwischen 0° und 50".The esterification can be carried out in the presence of an inert solvent will. Amides such as dimethylformamide, dimethylacetamide, 1,3-dimethyl-2-imidazolidinone or phosphoric acid hexamethyltriamide and sulfoxides such as dimethyl sulfoxide or sulfolane. The esterification can also be beneficial in the absence a solvent, e.g. B. by simply mixing the components, possibly in the presence of a strong acid. The reaction temperature is usually between -200 and 800, preferably between 0 ° and 50 ".
Bei diesen Temperaturen sind die Veresterungsreaktionen in der Regel nach 15 Minuten bis 48 Stunden beendet.The esterification reactions are usually at these temperatures Finished in 15 minutes to 48 hours.
Im einzelnen hängen die Reaktionsbedingungen für die Veresterung weitgehend von der Natur der verwendeten Säuren (oder deren reaktionsfähigen Derivate) ab. So wird eine freie Carbonsäure in der Regel in Gegenwart einer starken Säure, beispielsweise einer Mineralsäure wie Salzsäure oder Schwefelsäure, umgesetzt. Eine bevorzugte Reaktionsweise ist die Umsetzung eines Säureanhydrids (vorzugsweise eines Carbonsäureanhydrids wie Essigsäureanhydrid, Propionsäureanhydrid oder Buttersäureanhydrid) oder eines Säurechlorids mit dem Reaktionsgemisch. Diese Umsetzung wird vorzugsweise in einem sauren Milieu durchgeführt, wobei als Säuren Mineralsäuren wie Salzsäure oder Schwefelsäure, organische Säuren wie p-Toluolsulfonsäure oder auch Lewis-Säuren von Bedeutung sind.In detail, the reaction conditions for the esterification largely depend on the nature of the acids (or their reactive derivatives) used. So a free carboxylic acid is usually in the presence of a strong acid, for example a mineral acid such as hydrochloric acid or sulfuric acid. A preferred one The reaction is the conversion of an acid anhydride (preferably a carboxylic acid anhydride such as acetic anhydride, propionic anhydride or butyric anhydride) or one Acid chloride with the reaction mixture. This implementation is preferably done in one acidic environment, the acids being mineral acids such as hydrochloric acid or sulfuric acid, Organic acids such as p-toluenesulfonic acid or Lewis acids are important.
Die Umsetzung kann jedoch auch in einem basischen Milieu, beispielsweise in Gegenwart von Alkalimetallcarbonaten bzw. -hydrogencarbonaten wie Natriumcarbonat, Natriumhydrogencarbonat, Kaliumcarbonat oder Kaliumhydrogencarbonat, Alkalimetallacetate wie Natrium- oder Kaliumacetat, Erdalkalimetallhydroxide wie Calciumhydroxid oder organischen Basen wie Triethylamin, Pyridin, Lutidin, Kollidin oder Chinolin.The implementation can, however, also in a basic medium, for example in the presence of alkali metal carbonates or bicarbonates such as sodium carbonate, Sodium hydrogen carbonate, potassium carbonate or potassium hydrogen carbonate, alkali metal acetates such as sodium or potassium acetate, alkaline earth metal hydroxides such as calcium hydroxide or organic bases such as triethylamine, pyridine, lutidine, collidine or quinoline.
Als Säuren kommen insbesondere aliphatische Carbonsäuren (beispielsweise Essigsäure, Propionsäure, Buttersäure) oder aromatische Carbonsäuren (beispielsweise Benzoesäure) in Frage. Es können auch substituierte Benzoesäuren verwendet werden.In particular, aliphatic carboxylic acids (for example Acetic acid, propionic acid, butyric acid) or aromatic carboxylic acids (for example Benzoic acid). Substituted benzoic acids can also be used.
Das Reaktionsgemisch der Veresterung wird in an sich bekannter Weise aufgearbeitet und das Ester-Derivat der myo-Inosose durch Kristallisation aus einen geeigneten Lösungsmittel erhalten. Als Lösungsmittel gut geeignet sind insbesondere Ether wie Diethylether, Di-isopropylether, Di-n-propylether oder Di-n-butylether, Ketone wie Aceton oder Methylethylketon, Alkohole wie Methanol, Ethanol, n-Propanol oder iso-Propanol, Ester wie Ethylacetat oder Gemische solcher Lösungsmittel. Besonders bevorzugt sind Lösungsmittelgemische, die überwiegend aus Ether bestehen und 1 bis 10, insbesondere 2 bis 5 Vol.% Alkohol enthalten.The esterification reaction mixture is carried out in a manner known per se worked up and the ester derivative of myo-inosose by crystallization from a suitable solvent obtained. Particularly suitable solvents are Ethers such as diethyl ether, di-isopropyl ether, di-n-propyl ether or di-n-butyl ether, Ketones such as acetone or methyl ethyl ketone, alcohols such as methanol, ethanol, n-propanol or isopropanol, esters such as ethyl acetate or mixtures of such solvents. Particularly Solvent mixtures which predominantly consist of ethers and 1 to are preferred 10, in particular 2 to 5% by volume of alcohol.
Die gut kristallisierenden Ester-Derivate der myo-Inosose sind weitestgehend frei von Ester-Derivaten des myo-Inosits und können ohne weitere Reinigung zur Darstellung von scyllo-Inosit oder auch für andere Verwendungszwecke eingesetzt werden. Eine weitere Umkristallisation führt in der Regel zu einer Absenkung des Schmelzpunktes.The well-crystallizing ester derivatives of myo-inosose are largely free of ester derivatives of myo-inositol and can be used for representation without further purification by scyllo-inositol or for other purposes. One further recrystallization usually leads to a lowering of the melting point.
Die Reduktion und Hydrolyse der Ester-Derivate der myo-Inosose zu scyllo-Inosit kann prinzipiell nach allen bekannten Verfahren erfolgen, vorzugsweise durch eine Abwandlung bzw. Kombination bekannter Vorschriften [A. Kirsch, C. von Sonntag und D. Schulte-Frohlinde, J. Chem. Soc., Perkin II, 1975, 1334 und N. Z. Stanazev und M. Kates, J. Org. Chem. 26, 912 (1961)]. Das Esterderivat der myo-Inosose wird mit Natriumborhydrid/Methanol reduziert. Zur Abtrennung des Borates wird das Reaktionsgemisch nach Ansäuerung mehrmals mit Methanol versetzt und dasselbige ohne Vakuum abdestilliert. Aus dem Rückstand wird durch Kristallisation reiner scyllo-Inosit erhalten.The reduction and hydrolysis of the ester derivatives of myo-inosose too In principle, scyllo-inositol can be carried out by all known methods, preferably through a modification or combination of known regulations [A. Kirsch, C. von Sonntag and D. Schulte-Frohlinde, J. Chem. Soc., Perkin II, 1975, 1334 and N.Z. Stanazev and M. Kates, J. Org. Chem. 26, 912 (1961)]. The ester derivative of myo-inososis is reduced with sodium borohydride / methanol. To separate the borate, the After acidification, the reaction mixture is mixed several times with methanol and the same without Distilled off under vacuum. Crystallization turns the residue into pure scyllo-inositol obtain.
Das folgende Beispiel soll die Erfindung erläutern, ohne sie zu begrenzen: Darstellung des Platinkatalysators: 8,5 g Platin-II-oxid werden in 125 ml Wasser unter Rühren bei Raumtemperatur unter Normaldruck hydriert, bis die Wasserstoffaufnahme praktisch beendet bzw. deutlich verlangsamt ist (ca. 24 h). Dabei ist eine Überhydrierung, kenntlich durch Abscheidung eines Metallspiegels bzw. von Metallflittern, zu vermeiden, da sonst die Wirksamkeit abnimmt. Die so erhaltene Platinsuspension wird durch mehrfache Evakuierung von Wasserstoff befreit und kann direkt für die nachfolgende Vorschrift eingesetzt werden.The following example is intended to explain the invention without limiting it: Presentation of the platinum catalyst: 8.5 g of platinum (II) oxide are dissolved in 125 ml of water hydrogenated with stirring at room temperature under normal pressure until hydrogen uptake has practically ended or slowed down significantly (approx. 24 h). This is an overhydration, identified by the deposition of a metal mirror or metal flakes, to be avoided, otherwise the effectiveness will decrease. The platinum suspension thus obtained is by multiple Evacuation of hydrogen freed and can go directly to the following regulation can be used.
Der Katalysator kann für mehrere Reaktionscyclen verwendet werden.The catalyst can be used for several reaction cycles.
Penta-O-acetyl-myo-inosose: In eine Mischung aus 700 ml Wasser, 16,0 g myo-Inosit und dem aus 8,5 g Platin-II-oxid durch Hydrierung erhaltenen Pt-Katalysator wird unter Rühren bei 50-55 OC für 5 Stunden ein Sauerstoffstrom eingeleitet. Der Katalysator wird dann abfiltriert und kann wiederholt verwendet werden. Das Filtrat wird eingedampft und das Reaktionsprodukt wird unter Eiskühlung mit einer Mischung aus 106 ml Acetanhydrid und 6 ml konz. Schwefelsäure versetzt und 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird auf 500 ml Wasser gegossen, dreimal mit Ethylacetat extrahiert und die vereinigten organischen Phasen werden je dreimal mit 100 ml gesättigter Natriumhydrogencarbonat- und Natriumchloridlösung gewaschen, über Magnesiumsulfat getrocknet, filtriert und eingedampft. Der Rückstand wird zunächst mit 10 ml Methanol und dann mit 300-400 ml Ether versetzt und über Nacht kalt gestellt. Der gebildete Kristallniederschlag wird abgesaugt und mit Ether nachgewaschen.Penta-O-acetyl-myo-inosose: In a mixture of 700 ml of water, 16.0 g myo-inositol and the Pt catalyst obtained from 8.5 g platinum (II) oxide by hydrogenation a stream of oxygen is passed in with stirring at 50-55 ° C. for 5 hours. Of the Catalyst is then filtered off and can be used repeatedly. The filtrate is evaporated and the reaction product is cooled with ice with a mixture from 106 ml of acetic anhydride and 6 ml of conc. Sulfuric acid added and 24 hours Room temperature stirred. The reaction mixture is poured onto 500 ml of water, three times extracted with ethyl acetate and the combined organic phases are each three times washed with 100 ml of saturated sodium hydrogen carbonate and sodium chloride solution, dried over magnesium sulfate, filtered and evaporated. The residue is initially with 10 ml of methanol and then mixed with 300-400 ml of ether and over Chilled out at night. The crystal precipitate formed is filtered off with suction and washed with ether rewashed.
Ausbeute: 4-6 g, Schmp.: 205-209 OC.Yield: 4-6 g, m.p .: 205-209 OC.
Das so erhaltene Pentaacetat zeigt im 400 MHz NMR-Spekrum noch geringe Verunreinigung durch das Hexaacetat von myo-Inosit, kann aber ohne weitere Reinigung zur Darstellung von scyllo-Inosit eingesetzt werden.The pentaacetate obtained in this way still shows little in the 400 MHz NMR spectrum Contamination by the hexaacetate of myo-inositol, but can occur without further purification can be used to represent scyllo-inositol.
Scyllo-Inosit: Zu einer Suspension von 5,0 g Pentaacetat der myo-Inosose in 125 ml absol. Methanol wird unter Rühren bei Raumtemperatur die Lösung von 0,75 g Natriumborhydrid in 125 ml absol. Methanol getropft und noch 30 min bei Raumtemperatur gerührt. Die Lösung wird mit 2n Salzsäure angesäuert und auf 20 ml eingeengt. Zur Abtrennung des Borates wird noch mehrmals mit 200 ml Methanol versetzt und abdestilliert. Anschließend wird zur Trockne eingedampft, der Rückstand in 30-50 ml Wasser gelöst, über eine Kationenaustauschersäule (100 g Levatit SC 102 H) filtriert und mit Wasser nachgewaschen, bis das Filtrat neutral reagiert. Die wäßrige Lösung wird bis auf ca. 20 ml eingeengt, mit 200-250 ml Methanol versetzt und kalt gestellt.Scyllo-Inositol: To a suspension of 5.0 g of pentaacetate of myo-inosose in 125 ml absolute Methanol becomes the solution of 0.75 while stirring at room temperature g sodium borohydride in 125 ml absol. Added dropwise methanol and a further 30 min at room temperature touched. The solution is acidified with 2N hydrochloric acid and concentrated to 20 ml. To the Separation of the borate is mixed several times with 200 ml of methanol and distilled off. It is then evaporated to dryness, the residue is dissolved in 30-50 ml of water, filtered through a cation exchange column (100 g Levatit SC 102 H) and washed with water washed until the filtrate reacts neutrally. The aqueous solution is up to about 20 ml concentrated, mixed with 200-250 ml of methanol and placed cold.
Das als feine, farblose Kristalle abgeschiedene scyllo-Inosit wird abgesaugt und mit Methanol nachgewaschen.The scyllo-inositol deposited as fine, colorless crystals becomes suctioned off and washed with methanol.
Ausbeute: 1,6-1,8 g, Schmp.: 345-347 OC.Yield: 1.6-1.8 g, m.p .: 345-347 OC.
Durch Einengen der Mutterlauge kann ein zweites, weniger reines Kristallisat erhalten werden.Concentration of the mother liquor produces a second, less pure crystallizate can be obtained.
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843405663 DE3405663A1 (en) | 1984-02-17 | 1984-02-17 | Process for the preparation of scyllo-inositol |
| JP2663085A JPS60248637A (en) | 1984-02-17 | 1985-02-15 | Manufacture of scylloinositol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843405663 DE3405663A1 (en) | 1984-02-17 | 1984-02-17 | Process for the preparation of scyllo-inositol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3405663A1 true DE3405663A1 (en) | 1985-08-22 |
Family
ID=6227974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843405663 Withdrawn DE3405663A1 (en) | 1984-02-17 | 1984-02-17 | Process for the preparation of scyllo-inositol |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS60248637A (en) |
| DE (1) | DE3405663A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091596A (en) * | 1990-12-20 | 1992-02-25 | Univ. Of Va. Alumni Patents Foundation | Method for producing chiro-inositol |
| WO2000075355A1 (en) * | 1999-06-07 | 2000-12-14 | Hokko Chemical Industry Co., Ltd. | Novel process for producing l-epi-2-inosose and novel process for producing epi-inositol |
| EP1674578A4 (en) * | 2003-10-14 | 2007-03-14 | Hokko Chem Ind Co | PROCESS FOR PRODUCING SCYLLO-INOSITOL |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2011100670A1 (en) * | 2010-02-15 | 2011-08-18 | Abbott Laboratories | Process for the preparation of scyllo-inositol |
| WO2012051395A1 (en) | 2010-10-13 | 2012-04-19 | Elan Pharmaceuticals, Inc. | Methods of synthesis of scyllitol and related compounds |
| WO2013115012A1 (en) | 2012-02-02 | 2013-08-08 | 旭化成ケミカルズ株式会社 | Method for producing scyllo-inositol |
| EP2656839A1 (en) | 2007-04-12 | 2013-10-30 | Waratah Pharmaceuticals, Inc. | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases |
| WO2017029353A1 (en) | 2015-08-20 | 2017-02-23 | Transition Therapeutics Ireland Limited | Treatment of behaviors in dementia patients |
| WO2018004307A1 (en) | 2016-06-30 | 2018-01-04 | 씨제이제일제당 (주) | Method for enzymatically preparing highly concentrated myo-inositol |
-
1984
- 1984-02-17 DE DE19843405663 patent/DE3405663A1/en not_active Withdrawn
-
1985
- 1985-02-15 JP JP2663085A patent/JPS60248637A/en active Pending
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091596A (en) * | 1990-12-20 | 1992-02-25 | Univ. Of Va. Alumni Patents Foundation | Method for producing chiro-inositol |
| WO2000075355A1 (en) * | 1999-06-07 | 2000-12-14 | Hokko Chemical Industry Co., Ltd. | Novel process for producing l-epi-2-inosose and novel process for producing epi-inositol |
| US7157268B2 (en) * | 1999-06-07 | 2007-01-02 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol using microorganisms |
| US9833420B2 (en) | 2003-02-27 | 2017-12-05 | JoAnne McLaurin | Methods of preventing, treating, and diagnosing disorders of protein aggregation |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US8859628B2 (en) | 2003-02-27 | 2014-10-14 | JoAnne McLaurin | Method for preventing, treating and diagnosing disorders of protein aggregation |
| US8409833B2 (en) | 2003-10-14 | 2013-04-02 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| US8715974B2 (en) | 2003-10-14 | 2014-05-06 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| EP1674578A4 (en) * | 2003-10-14 | 2007-03-14 | Hokko Chem Ind Co | PROCESS FOR PRODUCING SCYLLO-INOSITOL |
| EP2058390A1 (en) | 2003-10-14 | 2009-05-13 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| US7745671B2 (en) | 2003-10-14 | 2010-06-29 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| EP2298870A1 (en) | 2003-10-14 | 2011-03-23 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| EP2656839A1 (en) | 2007-04-12 | 2013-10-30 | Waratah Pharmaceuticals, Inc. | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases |
| WO2011100670A1 (en) * | 2010-02-15 | 2011-08-18 | Abbott Laboratories | Process for the preparation of scyllo-inositol |
| WO2012051395A1 (en) | 2010-10-13 | 2012-04-19 | Elan Pharmaceuticals, Inc. | Methods of synthesis of scyllitol and related compounds |
| US8889921B2 (en) | 2010-10-13 | 2014-11-18 | Transition Therapeutics Ireland Limited | Methods of synthesis of scyllitol and related compounds |
| WO2013115012A1 (en) | 2012-02-02 | 2013-08-08 | 旭化成ケミカルズ株式会社 | Method for producing scyllo-inositol |
| US9505795B2 (en) | 2012-02-02 | 2016-11-29 | Asahi Kasei Chemicals Corporation | Method for producing scyllo-inositol |
| WO2017029353A1 (en) | 2015-08-20 | 2017-02-23 | Transition Therapeutics Ireland Limited | Treatment of behaviors in dementia patients |
| WO2018004307A1 (en) | 2016-06-30 | 2018-01-04 | 씨제이제일제당 (주) | Method for enzymatically preparing highly concentrated myo-inositol |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60248637A (en) | 1985-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3405663A1 (en) | Process for the preparation of scyllo-inositol | |
| DE2537681A1 (en) | PROCESS FOR THE PREPARATION OF THE ISOMERS 1,4-DIBROME-EPOXY-CYCLOHEXENE | |
| DE69014378T2 (en) | Intermediates, usable for the synthesis of delphinidine chloride. | |
| Morgan et al. | Ethyl Hydrogen DL-Galactarate and Ethyl DL-Galactarate Lactone, and Their Conversion to a Derivative of α-Pyrone1 | |
| DE877141C (en) | Process for the production of derivatives of uronic acids or the uronic acids themselves | |
| DE1178843B (en) | Process for the production of decoctions of 2,3-dimethoxy-5-methyl-1,4-benzohydroquinones and -quinones | |
| DE1288602B (en) | Process for making steroid compounds | |
| DE2301358B2 (en) | Process for the production of hydroxy-L-proline or N-acetyl-hydroxy-L-proline from hydrolyzed gelatin | |
| DE60004054T2 (en) | NEW METHOD FOR PRODUCING 17BETA-HYDROXY-17ALPHA-METHYL-2-OXA-5ALPHA-ANDROSTANE-3-ON | |
| DE2246867A1 (en) | TETRAHYDROXY-BICYCLO- SQUARE BRACKET ON 3.3.0 SQUARE BRACKET TO -OCTANE | |
| DE1264441B (en) | Process for the production of 17alpha-AEthynyl-delta 5 (10-19-nor-androsten-17beta-ol-3-one and 17alpha-AEthynil-19-nor-testosterone and its esters | |
| DE2350680C3 (en) | Process for the preparation of derivatives of (-) -podocarpenic acid which are substituted on the ring | |
| DE825686C (en) | Process for the conversion of í¸-20-cyanpregnenes with one or more nucleus-bound hydroxyl groups into 17 alpha-oxy-20-ketopregnanes | |
| AT224821B (en) | Process for the preparation of Δ1, 4-pregnadiene-17α, 21-diol-3, 20-dione | |
| AT242690B (en) | Process for the preparation of derivatives of 2,3-dimethoxy-5-methyl-benzohydroquinone- (1,4) and the associated quinones | |
| EP0276653B1 (en) | Process for the preparation of esters of bicyclo[3.3.0]octane-3,7-dionecarboxylic acid | |
| DE896646C (en) | Process for the selective oxidation of the 3-oxy group in A17-3, 21-dioxy-11-keto-20-cyanpregnen | |
| AT218182B (en) | Process for the preparation of an acyloxy derivative of Δ 5, 16-Pregnadien-3 β-o1-20-one | |
| DE69409427T2 (en) | Process for the preparation of hydroxyphenylacetic acids | |
| AT264723B (en) | Process for the preparation of new colchicine derivatives | |
| DE870408C (en) | Process for the preparation of 17-monoesters of androstane-3-cis-17-trans-diol | |
| DE69301345T2 (en) | Process for the preparation of 4-deoxy-D-mannose | |
| AT160572B (en) | Process for the preparation of unsaturated oxyketones of the cyclopentanopolydrophenanthrene series or their derivatives. | |
| CH374995A (en) | Process for making new steroid compounds | |
| DE1100628B (en) | Process for the preparation of? 1, 4-pregnadiene-17ª ‡, 21-diol-3,20-dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |